We are live on ! Find out more
PFM

Privium Fund Management Portfolio holdings

AUM $544M Turnover 27.14%
1-Year Est. Return 72.49%
This Fund
S&P 500
This Quarter Est. Return
+10.91%
1 Year Est. Return
+72.49%
3 Year Est. Return
+451.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$392M
AUM Growth
+$17.6M
Cap. Flow
+$3.68M
Cap. Flow %
0.94%
Top 10 Hldgs %
60.17%
Holding
139
New
22
Increased
37
Reduced
35
Closed
10
Avg Time Held
1.2 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.3 years

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$7.69M
2
ALXO icon
ALX Oncology
ALXO
+$4.88M
3
AMD icon
Advanced Micro Devices
AMD
+$4.75M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$1.56M
5
ASTSW icon
AST SpaceMobile, Inc. Warrant
ASTSW
+$1.51M

Top Sells

Rank Stock Value
1
SPOT icon
Spotify
SPOT
+$6.02M
2
FUSN icon
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$5.35M
3
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$3.37M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$3.3M
5
MRNA icon
Moderna
MRNA
+$2.1M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 24.59%
2 Healthcare 24.36%
3 Technology 24.32%
4 Communication Services 14.32%
5 Miscellaneous 8.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CPNG icon
26
Coupang
CPNG
$25.7B
$4.24M 1.08%
201,900
+5,000
+3% +$108K
2024 Q1
1 quarter
ZLAB icon
27
Zai Lab
ZLAB
$2.6B
$3.75M 0.96%
215,789
-24,894
-10% -$438K
2021 Q4
10 quarters
ASTSW icon
28
DELISTED
AST SpaceMobile, Inc. Warrant
ASTSW
$3.71M 0.95%
+1,034,275
New +$1.51M
2024 Q2
0 quarters
MRNA icon
29
Moderna
MRNA
$87B
$2.72M 0.69%
23,261
-16,600
-42% -$2.1M
2022 Q1
9 quarters
QURE icon
30
uniQure
QURE
$1.51B
$2.57M 0.66%
640,416
+61,501
+11% +$299K
2021 Q4
10 quarters
ACAD icon
31
Acadia Pharmaceuticals
ACAD
$3.29B
$2.35M 0.6%
148,400
– –
2024 Q1
1 quarter
ALXO icon
32
ALX Oncology
ALXO
$147M
$2.27M 0.58%
+396,966
New +$4.88M
2024 Q2
0 quarters
HEI.A icon
33
HEICO Corp Class A
HEI.A
$32.6B
$2.11M 0.54%
11,865
– –
2022 Q4
6 quarters
GRND.WS icon
34
DELISTED
Grindr Inc. Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
GRND.WS
$2.03M 0.52%
701,118
+98,788
+16% +$220K
2023 Q3
3 quarters
CLBTW icon
35
DELISTED
Cellebrite DI Ltd. Warrants
CLBTW
$1.81M 0.46%
643,948
-5,479
-0.8% -$12.9K
2023 Q4
2 quarters
SMR.WS icon
36
DELISTED
NuScale Power Corporation Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
SMR.WS
$1.71M 0.43%
690,449
+243,476
+54% +$316K
2024 Q1
1 quarter
BIIB icon
37
Biogen
BIIB
$34.4B
$1.6M 0.41%
7,000
-160
-2% -$34.8K
2022 Q4
6 quarters
UAA icon
38
Under Armour
UAA
$2.04B
$1.46M 0.37%
226,200
+3,300
+1% +$22.5K
2023 Q2
4 quarters
CRSP icon
39
CRISPR Therapeutics
CRSP
$4.76B
$1.45M 0.37%
27,347
+14,600
+115% +$845K
2023 Q1
5 quarters
ABEV icon
40
Ambev
ABEV
$50.7B
$1.31M 0.33%
635,914
+176,672
+38% +$402K
2022 Q1
9 quarters
KRYS icon
41
Krystal Biotech
KRYS
$9.37B
$1.14M 0.29%
6,420
+1,920
+43% +$322K
2022 Q1
9 quarters
BF.B icon
42
Brown-Forman Class B
BF.B
$13.3B
$1.1M 0.28%
25,800
– –
2023 Q2
4 quarters
PFE icon
43
Pfizer
PFE
$169B
$1.01M 0.26%
36,120
+6,960
+24% +$192K
2023 Q4
2 quarters
FOX icon
44
Fox Class B
FOX
$24.1B
$998K 0.25%
30,900
– –
2024 Q1
1 quarter
IMTXW icon
45
DELISTED
Immatics N.V. Warrants
IMTXW
$902K 0.23%
295,814
+45,231
+18% +$127K
2023 Q2
4 quarters
RNAM
46
DELISTED
Avidity Biosciences
RNAM
$863K 0.22%
22,242
+14,200
+177% +$407K
2024 Q1
1 quarter
FDMT icon
47
4D Molecular Therapeutics
FDMT
$671M
$823K 0.21%
40,000
+9,000
+29% +$226K
2023 Q3
3 quarters
C icon
48
Citigroup
C
$208B
$807K 0.21%
12,478
-2,100
-14% -$129K
2021 Q4
10 quarters
MGTX icon
49
MeiraGTx Holdings
MGTX
$891M
$804K 0.21%
203,960
+83,975
+70% +$424K
2024 Q1
1 quarter
NOV icon
50
NOV
NOV
$6.75B
$734K 0.19%
39,719
-4,900
-11% -$91.8K
2021 Q4
10 quarters
1
2
3 4 5

Similar funds

RWMH
Riverpoint Wealth Management Holdings Chicago, Illinois $544M AUM 20.39% 1-Year Est. Return
BPIA
Broad Peak Investment Advisers Singapore $544M AUM 132.56% 1-Year Est. Return
AFA
Abacus FCF Advisors Orlando, Florida $544M AUM 70.51% 1-Year Est. Return
TC
TownSquare Capital Provo, Utah $544M AUM 40.38% 1-Year Est. Return
FIM
FWL Investment Management Dallas, Texas $545M AUM 64.06% 1-Year Est. Return
DKAM
Drummond Knight Asset Management Crows Nest, NSW, Australia $545M AUM 73.62% 1-Year Est. Return
CCM
Coerente Capital Management Toronto, Ontario, Canada $543M AUM 7.53% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Privium Fund Management's Q2 2024 Portfolio in Review

As of Q2 2024, Privium Fund Management held 139 positions worth $392M, up 4.7% from $374M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Privium Fund Management's Q2 2024 filing shows 22 new, 37 increased, 35 reduced and 10 closed positions. Its largest new stake was ALX Oncology: 396,966 shares worth $2.27M. The largest sale was Spotify, an estimated $6.02M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 25% of assets, up from 19% a quarter earlier, followed by Healthcare and Technology.

  • Privium Fund Management's largest Q2 2024 buy was ALX Oncology: 396,966 shares worth $2.27M.
  • Privium Fund Management added most to Tesla in Q2 2024, an estimated $7.69M increase.
  • Privium Fund Management's biggest Q2 2024 reduction was Spotify, cutting an estimated $6.02M.
  • Privium Fund Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $5.35M.
  • Privium Fund Management's ten largest holdings make up 60% of its $392M portfolio in Q2 2024.
  • Privium Fund Management opened 22 new positions and closed 10 in Q2 2024.
  • Privium Fund Management's portfolio value rose 4.7% quarter-over-quarter to $392M.

Based on Privium Fund Management's 13F filing for Q2 2024, filed 1 Aug 2024.